ICCC Q3 2021 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+38.4% YoY

Gross Profit

$2M47.0% margin

Operating Income

$271,0905.3% margin

Net Income

$147,7642.9% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+13.4%

Cash Flow

Operating Cash Flow

$258,991

Free Cash Flow

-$416,409

Stock-Based Comp.

$45,488

Balance Sheet

Total Assets

$44M

Total Liabilities

$12M

Stockholders' Equity

$32M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+38.4%
Gross Profit	$2M	$2M	+40.4%
Operating Income	$271,090	-$251,598	+207.7%
Net Income	$147,764	-$322,888	+145.8%

Revenue Segments

FirstDefenseProductLineMember

$5M98%

OtherAnimalHealthMember

$116,7452%

Geographic Segments

UNITED STATES

$5M88%

OtherStatesMember

$599,83012%